186 related articles for article (PubMed ID: 35261799)
1. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.
Wu R; Oshi M; Asaoka M; Huyser MR; Tokumaru Y; Yamada A; Yan L; Endo I; Ishikawa T; Takabe K
Am J Cancer Res; 2022; 12(2):744-762. PubMed ID: 35261799
[TBL] [Abstract][Full Text] [Related]
2. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
3. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
[TBL] [Abstract][Full Text] [Related]
4. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
[TBL] [Abstract][Full Text] [Related]
5. Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).
Tokumaru Y; Oshi M; Murthy V; Tian W; Yan L; Angarita FA; Nagahashi M; Matsuhashi N; Futamura M; Yoshida K; Miyoshi Y; Takabe K
Am J Cancer Res; 2021; 11(11):5743-5755. PubMed ID: 34873491
[TBL] [Abstract][Full Text] [Related]
6. Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Oshi M; Kawaguchi T; Yan L; Peng X; Qi Q; Tian W; Schulze A; McDonald KA; Narayanan S; Young J; Liu S; Morris LG; Chan TA; Kalinski P; Matsuyama R; Otsuji E; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3628-3644. PubMed ID: 34354864
[TBL] [Abstract][Full Text] [Related]
7. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
8. Conflicting roles of
Oshi M; Gandhi S; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Ishikawa T; Endo I; Takabe K
Am J Cancer Res; 2021; 11(10):5094-5110. PubMed ID: 34765314
[TBL] [Abstract][Full Text] [Related]
9. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
[TBL] [Abstract][Full Text] [Related]
10. Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis.
Okano M; Oshi M; Butash AL; Katsuta E; Tachibana K; Saito K; Okayama H; Peng X; Yan L; Kono K; Ohtake T; Takabe K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461932
[TBL] [Abstract][Full Text] [Related]
11. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
12. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
13. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
14. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
[TBL] [Abstract][Full Text] [Related]
15. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
17. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
[TBL] [Abstract][Full Text] [Related]
18. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer.
Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371179
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer.
Oshi M; Patel A; Wu R; Le L; Tokumaru Y; Yamada A; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
NPJ Breast Cancer; 2022 Aug; 8(1):92. PubMed ID: 35945417
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
